Cryo-Cell International, Inc. Overview
Pro stress-test →Cryo-Cell International is the world's first private cord blood bank, specializing in the collection, processing, and cryogenic storage of umbilical cord blood and tissue stem cells for family use. The company serves as a regenerative medicine enabler, preserving cellular material that may be used therapeutically to treat a range of medical conditions. With over 500,000 customers across 87 countries, Cryo-Cell operates a proven recurring revenue model centered on long-term specimen storage.
Strategic Profile
Pro stress-test →Cryo-Cell maintains a competitive moat as the pioneering and internationally recognized leader in private cord blood banking. The company operates across three segments: family cord blood and tissue banking, manufacturing of proprietary PrepaCyte CB processing systems for other cord blood banks, and public cord blood banking services. Its direct-to-parent marketing strategy combined with healthcare professional partnerships provides consistent customer acquisition channels.
Competitive Landscape
Pro stress-test →Cryo-Cell competes in the niche private cord blood banking market against companies like Americord, Cord Blood Registry, and others offering similar storage services. The broader regenerative medicine and stem cell therapy market is expanding, but clinical validation of cord blood applications remains in early stages. Competition from public cord blood banking networks and emerging cellular therapies may impact long-term growth. Cryo-Cell's competitive advantage lies in first-mover status, operational track record, and established customer base rather than proprietary technology.
Industry Context
Cryo-Cell International, Inc. operates in Cellular Processing & Cryogenic Storage / Regenerative Medicine / Cord Blood Banking.
Key facts
Founded: 1989 · Headquarters: Oldsmar, Florida, United States · Employees: Not disclosed in search results · Revenue: Not disclosed in search results · Market cap: $27.6M - $36M